Long Term Depression (Ltd) In Neurodegeneration represents a key pathological mechanism in neurodegenerative diseases. This page explores the molecular and cellular processes involved, their contribution to disease progression, and therapeutic implications. [1]
Long-term depression (LTD) is a type of synaptic plasticity characterized by a persistent weakening of synaptic strength. Unlike long-term potentiation (LTP), which strengthens synapses, LTD reduces the efficiency of synaptic transmission. This process is essential for synaptic homeostasis, learning, and memory refinement. However, dysregulation of LTD has been implicated in the pathogenesis of neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, and Amyotrophic Lateral Sclerosis (ALS). [2]
NMDA receptor-dependent LTD is the most extensively studied form of LTD. It requires: [3]
The calcium influx activates calcium/calmodulin-dependent protein kinase II (CaMKII), which paradoxically can trigger LTD under low-frequency stimulation conditions through phosphatase activation. [4]
mGluR-dependent LTD is induced by activation of group I metabotropic glutamate receptors (mGluR1 and mGluR5). This form of LTD: [5]
| Feature | NMDAR-LTD | mGluR-LTD | [6]
|---------|-----------|-----------| [7]
| Induction | Low-frequency stimulation | Agonist application / paired stimulation | [8]
| Calcium source | NMDAR | Internal stores + voltage-gated calcium channels | [9]
| Time course | Slower onset (minutes) | Rapid onset | [10]
| Protein synthesis | Not required | Required |
| Key phosphatases | Calcineurin, PP1 | PP2A, PP1 |
The primary mechanism of LTD expression involves AMPA receptor internalization:
LTD serves critical homeostatic functions:
In Alzheimer's disease, LTD mechanisms are profoundly disrupted:
The amyloid cascade hypothesis now incorporates synaptic plasticity dysregulation including LTD as a key pathogenic mechanism.
In ALS:
The study of Long Term Depression (Ltd) In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
'Malenka RC, Bear MF. LTP and LTD: An Embarrassment of Riches. Neuron. 2004'. 2004. ↩︎
Collingridge GL, et al. The regulation of NMDA receptor signalling in neurodegeneration. J Neurochem. 2023. 2023. ↩︎
Henley JM, Wilkinson KA. Synaptic AMPA receptor trafficking in neurodegeneration. Neuropharmacology. 2022. 2022. ↩︎
Wang Y, et al. Amyloid-beta induces synaptic depression through a calcineurin-dependent pathway. Nat Neurosci. 2024. 2024. ↩︎
Hu NW, et al. mGlu5 receptors and amyloid pathology in Alzheimer's disease. Brain. 2023. 2023. ↩︎
Zhang Y, et al. Alpha-synuclein and synaptic plasticity. J Neurosci. 2024. 2024. ↩︎
Mancini M, et al. LTD in Parkinson's disease models. Mov Disord. 2023. 2023. ↩︎
Kim SH, et al. TDP-43 and synaptic plasticity in neurodegeneration. Acta Neuropathol. 2024. 2024. ↩︎
'Citri A, Malenka RC. Synaptic plasticity: Multiple forms, functions, and mechanisms. Neuropsychopharmacology. 2008'. 2008. ↩︎
Kessels HW, Malinow R. Synaptic AMPA receptor trafficking and Alzheimer's disease. Neuron. 2009. 2009. ↩︎